Embargo Watch

Keeping an eye on how scientific information embargoes affect news coverage

ASCO rituximab (Rituxan) lymphoma embargo broken

leave a comment »

It’s ASCO time, with the embargo on most conference abstracts lifting tonight at 6 p.m. Eastern, and the media circus has already tossed off one embargo break, according to an email sent out at 12:20 Eastern:

Due to an embargo break, the American Society of Clinical Oncology (ASCO) has lifted the embargo on the abstract titled, “Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.”

Reporters are free to publish stories on this study, which was supposed to be embargoed until 6:00 PM (EDT) today. A media summary of the study is copied below, along with the abstract.  ASCO is investigating the reasons for this embargo break.

I’ve learned that a release about the study went out early this morning on PR Newswire. The release was withdrawn, but not before the Swiss financial wire AWP wrote a story based on it. Rituxan manufacturer Roche notified some news outlets, who agreed to uphold the original 6 p.m. Eastern embargo given that it was one of such a large number of embargoed abstracts.

However, ASCO evidently found out, and lifted the embargo early, according to an email sent out at 12:20 Eastern:

Due to an embargo break, the American Society of Clinical Oncology (ASCO) has lifted the embargo on the abstract titled, “Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.”

Reporters are free to publish stories on this study, which was supposed to be embargoed until 6:00 PM (EDT) today. A media summary of the study is copied below, along with the abstract.  ASCO is investigating the reasons for this embargo break.

There will likely be updates, so check back if you’re interested — and I’ll tweet that there’s news.

Plug alert: This post probably would have been up sooner, except that I was interviewing Daniel Carlat, author of Unhinged: The Trouble With Psychiatry. I hope you’ll agree that talk — see highlights here — was very much worth it.

Update, 2:20 p.m. Eastern, 5/20/10: Here’s Reuters’ coverage of the study.

Written by Ivan Oransky

May 20, 2010 at 1:20 pm

Posted in Uncategorized

Tagged with ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: